A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers
Status:
Not yet recruiting
Trial end date:
2022-12-09
Target enrollment:
Participant gender:
Summary
Xfibra, Inc. is conducting a phase 1, randomised, double-blind, placebo-controlled,
first-in-human study of the safety, tolerability, and pharmacokinetics of single and multiple
ascending doses of XFB-19 in healthy adult volunteers in lung fibrosis.